Bitter pill for Sun Pharma, Sanofi wins US drug ruling

French drugmaker Sanofi has scored an important victory in a patent dispute with Sun Pharmaceuticals that will keep generic copies of its Eloxatin colon cancer drug off the United States market until August 2012.

hidden September 19, 2011 14:46:14 IST
Bitter pill for Sun Pharma, Sanofi wins US drug ruling

Paris: French drugmaker Sanofi has scored an important victory in a patent dispute with Sun Pharmaceuticals that will keep generic copies of its Eloxatin colon cancer drug off the United States market until August 2012.

Bitter pill for Sun Pharma Sanofi wins US drug ruling

If Sun had prevailed, other generics manufacturers could have launched their own copies of Eloxatin. Reuters

A ruling by the US District Court for the District of New Jersey maintained Sanofi's market exclusivity for Eloxatin in the United States through 9 August, 2012, Sanofi said in a statement on Monday.

Mumbai-based Sun had appealed an April 2010 ruling requiring the Indian company to stop selling its generic version of Eloxatin as of 30 June, 2010, Sanofi said.

If Sun had prevailed, other generics manufacturers could have launched their own copies of Eloxatin before 9 August.

Eloxatin sales were €248 million ($349 million) in the second quarter.

Reuters

Updated Date:

also read

Cipla loses US court appeal over animal healthcare product
Business

Cipla loses US court appeal over animal healthcare product

Pharmaceuticals major Cipla lost an appeal in the US court against Merial ltd, a subsidiary of Sanofi-Aventis for an animal healthcare product. Merial took Cipla to court saying the product infringed on a patent owned by Merial.

Sanofi deal creates buzz for Glenmark; re-rating likely
Investing

Sanofi deal creates buzz for Glenmark; re-rating likely

Macquarie finds Glenmark's valuation attractive and feels the market is not assigning any value to the company's innovation franchise because of a few setbacks in the past.

Weak European markets and inflation data play spoilsport
Investing

Weak European markets and inflation data play spoilsport

Weak opening by European markets and higher than expected inflation numbers pull the markets down further.